HBM Healthcare Investments is a publicly traded Swiss investment and venture capital firm focusing on emerging technologies in the global healthcare sector. It holds a globally diversified portfolio of private and public healthcare companies across biotechnology, medical technology, diagnostics, and therapeutics.
43% of their portfolio is in Biotech & Life Sciences. Deal activity increased 400% year-over-year (5 deals in the last 12 months). Average disclosed round size is $107.0M (across 48 rounds with reported amounts).
Portfolio
47
Fund Size
—
Top Stage
Series B
Last 12 Mo
6
Team
MF
Matthias Fehr
Head Private Equity
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
53 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| CCrystalys Therapeutics | Series B | $130M | Jul 2026 |
 FORE Biotherapeutics | Unknown | $67.4M | Jul 2026 |
 CellCentric | Series D | $220M | May 2026 |
 Corxel | Series D | $287M | Jan 2026 |
 Electra | Series C | $183M | Oct 2025 |
| EElectra Therapeutics | Series C | $183M | Oct 2025 |
| FORE Biotherapeutics | Series D | $38M | May 2025 |
| FFore Bio | Series D | $38M | May 2025 |
| CCurevo Vaccine | Series B | $110M | Jan 2025 |
| CCartesian | Unknown | $130M | Jul 2024 |
 Alumis | Series C | $259M | Mar 2024 |
| AAdaRx Pharmaceuticals | Series C | $200M | Aug 2023 |
| AAdarx | Series C | $46M | Jan 2023 |
 Odyssey Therapeutics | Series B | $168M | Oct 2022 |
 Upstream Bio | Series A | $200M | Jun 2022 |
| MMineralys | Series B | $118M | Jan 2022 |
| MMineralys Therapeutics, Inc. | Series B | $118M | Jan 2022 |
 Freenome | Series D | $300M | Dec 2021 |
| Odyssey Therapeutics | Series A | $218M | Dec 2021 |
| MMineralys | Series A | $40M | Apr 2021 |
| MMineralys Therapeutics, Inc. | Series A | $40M | Apr 2021 |
 Neurelis | Series D | $114M | Mar 2021 |
 Genalyte | Series C | $50M | Jan 2021 |
 Acrivon Therapeutics | Series B | $100M | Jan 2021 |
| MMineralys Therapeutics, Inc. | Series A | $40M | Jan 2021 |
Page 1 of 3
Top Co-Investors
OrbiMed19 shared
Cormorant Asset Management18 shared
SR One12 shared
RA Capital Management12 shared
Wellington Management9 shared
Samsara BioCapital8 shared
Catalys Pacific7 shared
Redmile Group6 shared
Bain Capital Life Sciences6 shared
Perceptive Advisors5 shared
T. Rowe Price5 shared
Logos Capital5 shared
Omega Funds5 shared
The Invus Group, LLC5 shared
Rock Springs Capital5 shared
Vivo Capital5 shared
Pivotal Life Sciences5 shared
Surveyor Capital4 shared
Alexandria Venture Investments4 shared
Last updated: 7 September 2026